Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.

Wan YL, Sapra P, Bolton J, Chua JX, Durrant LG, Stern PL.

Target Oncol. 2019 Aug;14(4):465-477. doi: 10.1007/s11523-019-00650-8.

2.

T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy.

Brentville VA, Symonds P, Cook KW, Daniels I, Pitt T, Gijon M, Vaghela P, Xue W, Shah S, Metheringham RL, Durrant LG.

Oncoimmunology. 2019 Feb 20;8(5):e1576490. doi: 10.1080/2162402X.2019.1576490. eCollection 2019.

3.

Novel tumour antigens and the development of optimal vaccine design.

Brentville VA, Atabani S, Cook K, Durrant LG.

Ther Adv Vaccines Immunother. 2018 Apr;6(2):31-47. doi: 10.1177/2515135518768769. Epub 2018 Apr 10. Review.

4.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG.

Oncoimmunology. 2018 Feb 22;7(6):e1433516. doi: 10.1080/2162402X.2018.1433516. eCollection 2018.

5.

Current Strategies to Enhance Anti-Tumour Immunity.

Cook KW, Durrant LG, Brentville VA.

Biomedicines. 2018 Mar 23;6(2). pii: E37. doi: 10.3390/biomedicines6020037. Review.

6.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer.

Machado LR, Moseley PM, Moss R, Deen S, Nolan C, Spendlove I, Ramage JM, Chan SY, Durrant LG.

Oncotarget. 2017 Aug 24;8(60):101215-101223. doi: 10.18632/oncotarget.20538. eCollection 2017 Nov 24.

7.

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.

Xue W, Brentville VA, Symonds P, Cook KW, Yagita H, Metheringham RL, Durrant LG.

Oncotarget. 2016 Dec 13;7(50):83088-83100. doi: 10.18632/oncotarget.13070.

8.

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.

Xue W, Metheringham RL, Brentville VA, Gunn B, Symonds P, Yagita H, Ramage JM, Durrant LG.

Oncoimmunology. 2016 Apr 22;5(6):e1169353. doi: 10.1080/2162402X.2016.1169353. eCollection 2016 Jun.

9.

Autophagy, citrullination and cancer.

Durrant LG, Metheringham RL, Brentville VA.

Autophagy. 2016 Jun 2;12(6):1055-6. doi: 10.1080/15548627.2016.1166326. Epub 2016 May 4.

10.

Cancer cell associated glycans as targets for immunotherapy.

Vankemmelbeke M, Chua JX, Durrant LG.

Oncoimmunology. 2015 Jul 15;5(1):e1061177. eCollection 2016.

11.

Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.

Brentville VA, Metheringham RL, Gunn B, Symonds P, Daniels I, Gijon M, Cook K, Xue W, Durrant LG.

Cancer Res. 2016 Feb 1;76(3):548-60. doi: 10.1158/0008-5472.CAN-15-1085. Epub 2015 Dec 30.

12.

Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.

Chua JX, Vankemmelbeke M, McIntosh RS, Clarke PA, Moss R, Parsons T, Spendlove I, Zaitoun AM, Madhusudan S, Durrant LG.

Clin Cancer Res. 2015 Jul 1;21(13):2963-74. doi: 10.1158/1078-0432.CCR-14-3030. Epub 2015 Mar 16.

13.

Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies.

Dingjan T, Spendlove I, Durrant LG, Scott AM, Yuriev E, Ramsland PA.

Mol Immunol. 2015 Oct;67(2 Pt A):75-88. doi: 10.1016/j.molimm.2015.02.028. Epub 2015 Mar 7. Review.

PMID:
25757815
14.

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.

Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG.

J Cancer Res Clin Oncol. 2015 Mar;141(3):505-14. doi: 10.1007/s00432-014-1822-0. Epub 2014 Sep 18.

PMID:
25230899
15.

Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer.

Albasri A, Fadhil W, Scholefield JH, Durrant LG, Ilyas M.

Anticancer Res. 2014 Aug;34(8):3969-74.

PMID:
25075018
16.

CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype.

Sutavani RV, Bradley RG, Ramage JM, Jackson AM, Durrant LG, Spendlove I.

J Immunol. 2013 Dec 15;191(12):5895-903. doi: 10.4049/jimmunol.1301458. Epub 2013 Nov 6.

17.

Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.

Noble P, Spendlove I, Harding S, Parsons T, Durrant LG.

PLoS One. 2013;8(2):e54892. doi: 10.1371/journal.pone.0054892. Epub 2013 Feb 8.

18.

Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla.

Storr SJ, Zaitoun AM, Arora A, Durrant LG, Lobo DN, Madhusudan S, Martin SG.

BMC Cancer. 2012 Nov 9;12:511. doi: 10.1186/1471-2407-12-511.

19.

High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment.

Brentville VA, Metheringham RL, Gunn B, Durrant LG.

PLoS One. 2012;7(7):e41112. doi: 10.1371/journal.pone.0041112. Epub 2012 Jul 19.

20.

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.

Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, Ramage JM.

Br J Cancer. 2012 Mar 27;106(7):1306-13. doi: 10.1038/bjc.2012.49. Epub 2012 Mar 13.

21.

Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Durrant LG, Noble P, Spendlove I.

Clin Exp Immunol. 2012 Feb;167(2):206-15. doi: 10.1111/j.1365-2249.2011.04516.x. Review.

22.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, HÃ¥kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

23.

Using monoclonal antibodies to stimulate antitumor cellular immunity.

Durrant LG, Pudney VA, Spendlove I.

Expert Rev Vaccines. 2011 Jul;10(7):1093-106. doi: 10.1586/erv.11.33. Review.

PMID:
21806402
24.

Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology.

Baxendale A, van Hooff P, Durrant LG, Spendlove I, Howdle SM, Woods HM, Whitaker MJ, Davies OR, Naylor A, Lewis AL, Illum L.

Int J Pharm. 2011 Jul 15;413(1-2):147-54. doi: 10.1016/j.ijpharm.2011.04.053. Epub 2011 Apr 28.

PMID:
21554938
25.

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer.

Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG.

Gut. 2010 Jul;59(7):926-33. doi: 10.1136/gut.2009.194472.

PMID:
20581241
26.

Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.

Durrant LG, Pudney V, Spendlove I, Metheringham RL.

Expert Opin Biol Ther. 2010 May;10(5):735-48. doi: 10.1517/14712591003769790. Review.

PMID:
20384522
27.

ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients.

McGilvray RW, Eagle RA, Rolland P, Jafferji I, Trowsdale J, Durrant LG.

Int J Cancer. 2010 Sep 1;127(6):1412-20. doi: 10.1002/ijc.25156.

28.

Antibodies designed as effective cancer vaccines.

Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Durrant LG.

MAbs. 2009 Jan-Feb;1(1):71-85.

29.

DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells.

Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, Durrant LG.

Eur J Immunol. 2010 Mar;40(3):899-910. doi: 10.1002/eji.200939857.

30.

Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer.

Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG.

Int J Gynecol Pathol. 2010 Jan;29(1):8-18. doi: 10.1097/PGP.0b013e3181b64ec3.

PMID:
19952944
31.

CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer.

Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M.

J Clin Pathol. 2009 Dec;62(12):1117-22. doi: 10.1136/jcp.2009.069310.

PMID:
19946098
32.

NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting.

McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG.

Clin Cancer Res. 2009 Nov 15;15(22):6993-7002. doi: 10.1158/1078-0432.CCR-09-0991. Epub 2009 Oct 27.

33.

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.

Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S.

Br J Cancer. 2009 Oct 20;101(8):1321-8. doi: 10.1038/sj.bjc.6605315. Epub 2009 Sep 15.

34.

T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG.

Clin Immunol. 2008 Aug;128(2):148-54. doi: 10.1016/j.clim.2008.03.512. Epub 2008 May 27.

PMID:
18508409
35.

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I, Durrant LG.

Clin Cancer Res. 2008 May 15;14(10):3030-5. doi: 10.1158/1078-0432.CCR-07-1888.

36.

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ.

Clin Cancer Res. 2008 Apr 1;14(7):2028-35. doi: 10.1158/1078-0432.CCR-07-4554.

37.

Upregulation of MICA on high-grade invasive operable breast carcinoma.

Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, Ellis I, Durrant LG.

Cancer Immun. 2007 Oct 22;7:17.

38.

Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients.

Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG.

Clin Cancer Res. 2007 Sep 1;13(17):5070-5.

39.

Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.

Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, Durrant LG.

Clin Cancer Res. 2007 Jul 15;13(14):4139-45.

40.

The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.

Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG.

World J Surg Oncol. 2007 Mar 9;5:31.

41.

A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

Ullenhag GJ, Spendlove I, Watson NF, Indar AA, Dube M, Robins RA, Maxwell-Armstrong C, Scholefield JH, Durrant LG.

Clin Cancer Res. 2006 Dec 15;12(24):7389-96. Epub 2006 Nov 22.

42.

Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients.

Watson NF, Durrant LG, Scholefield JH, Madjd Z, Scrimgeour D, Spendlove I, Ellis IO, Patel PM.

World J Gastroenterol. 2006 Oct 21;12(39):6299-304.

43.

Costimulation via CD55 on human CD4+ T cells mediated by CD97.

Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I.

J Immunol. 2006 Jul 15;177(2):1070-7.

44.

A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis.

Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T.

Cancer Res. 2006 Jun 1;66(11):5901-9.

45.

Complement decay accelerating factor (DAF)/CD55 in cancer.

Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG.

Cancer Immunol Immunother. 2006 Aug;55(8):987-95. Epub 2006 Feb 17.

PMID:
16485129
46.

The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2.

Ramage JM, Spendlove I, Rees R, Moss RS, Durrant LG.

Cancer Immunol Immunother. 2006 Aug;55(8):1004-10. Epub 2006 Jan 12.

PMID:
16408213
47.

Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.

Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG.

Int J Cancer. 2006 Mar 15;118(6):1445-52.

48.

High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.

Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG.

Breast Cancer Res. 2005;7(5):R780-7. Epub 2005 Jul 28.

49.

Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients.

Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I.

Cancer Immunol Immunother. 2006 Aug;55(8):973-80. Epub 2005 Sep 3.

PMID:
16151805
50.

Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients.

Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, Durrant LG.

World J Surg Oncol. 2005 Jul 19;3:47.

Supplemental Content

Loading ...
Support Center